The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of solaneuzumab, a drug that may have the potential to slow the onset of Alzheimer's disease (AD). In AD, there are abnormally high levels of a protein, called amyloid, in the brain. We hope that solaneuzumab can reduce the amount of amyloid in the brain.


We are looking for participants who:

  • Do not have a memory problem
  • Are between age 65 and 85
  • Have a reliable caregiver or family member who knows them well
  • Are in stable medical condition
  • Are willing to undergo MRI and PET scans

For more information about participation, please contact Kirsten Glennon, RN.


Download Flyer: